Risk Factors for Mortality among Patients with Pseudomonas aeruginosa Bloodstream Infections: What Is the Influence of XDR Phenotype on Outcomes?
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Risk Factors for Mortality among Patients with Pseudomonas aeruginosa Bloodstream Infections: What Is the Influence of XDR Phenotype on Outcomes?
Authors
Keywords
-
Journal
Journal of Clinical Medicine
Volume 9, Issue 2, Pages 514
Publisher
MDPI AG
Online
2020-02-25
DOI
10.3390/jcm9020514
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Geographic and Temporal Patterns of Antimicrobial Resistance in Pseudomonas aeruginosa Over 20 Years From the SENTRY Antimicrobial Surveillance Program, 1997–2016
- (2019) Dee Shortridge et al. Open Forum Infectious Diseases
- Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology
- (2019) Ester del Barrio-Tofiño et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Colistin plus meropenem combination is synergistic in vitro against extensively drug-resistant (XDR) Pseudomonas aeruginosa, including high-risk clones
- (2019) María M. Montero et al. Journal of Global Antimicrobial Resistance
- Weighting the impact of virulence on the outcome of Pseudomonas aeruginosa bloodstream infections
- (2019) Irina Sánchez-Diener et al. CLINICAL MICROBIOLOGY AND INFECTION
- Mortality dynamics of Pseudomonas aeruginosa bloodstream infections and the influence of defective OprD on mortality: prospective observational study
- (2019) Eun-Jeong Yoon et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections
- (2019) Juan P. Horcajada et al. CLINICAL MICROBIOLOGY REVIEWS
- Predictors of Mortality in Bloodstream Infections Caused by Pseudomonas aeruginosa: Impact of Antimicrobial Resistance and Bacterial Virulence
- (2019) Raúl Recio et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Risk factors for mortality among patients with Pseudomonas aeruginosa bacteremia – retrospective multicenter study
- (2019) Tanya Babich et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Evaluation of Ceftolozane-Tazobactam in Combination with Meropenem against Pseudomonas aeruginosa Sequence Type 175 in a Hollow-Fiber Infection Model
- (2018) M. Montero et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Bacteraemia due to extensively drug-resistant Pseudomonas aeruginosa sequence type 235 high-risk clone: Facing the perfect storm
- (2018) Raúl Recio et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial
- (2018) Mical Paul et al. LANCET INFECTIOUS DISEASES
- Epidemiology and risk factors of extensively drug-resistant Pseudomonas aeruginosa infections
- (2018) Nattawan Palavutitotai et al. PLoS One
- Active monotherapy and combination therapy for extensively drug-resistant Pseudomonas aeruginosa pneumonia
- (2018) Thana Khawcharoenporn et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Understanding the acute inflammatory response to Pseudomonas aeruginosa infection: differences between susceptible and multidrug-resistant strains in a mouse peritonitis model
- (2017) Silvia Gómez-Zorrilla et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Metabolic Compensation of Fitness Costs Is a General Outcome for Antibiotic-Resistant Pseudomonas aeruginosa Mutants Overexpressing Efflux Pumps
- (2017) Jorge Olivares Pacheco et al. mBio
- Carbapenem-Resistant Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure
- (2016) Deanna J. Buehrle et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Impact of multidrug resistance on the pathogenicity of Pseudomonas aeruginosa: in vitro and in vivo studies
- (2016) Silvia Gómez-Zorrilla et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
- (2016) Mervyn Singer et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Polymyxin B in Combination with Antimicrobials LackingIn VitroActivity versus Polymyxin B in Monotherapy in Critically Ill Patients with Acinetobacter baumannii or Pseudomonas aeruginosa Infections
- (2015) Maria Helena Rigatto et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The increasing threat of Pseudomonas aeruginosa high-risk clones
- (2015) Antonio Oliver et al. DRUG RESISTANCE UPDATES
- Extensively Drug-Resistant Pseudomonas aeruginosa Bacteremia in Solid Organ Transplant Recipients
- (2015) Marta Bodro et al. TRANSPLANTATION
- Influence of Virulence Genotype and Resistance Profile in the Mortality of Pseudomonas aeruginosa Bloodstream Infections
- (2014) C. Pena et al. CLINICAL INFECTIOUS DISEASES
- Characteristics, risk factors and outcomes of adult cancer patients with extensively drug-resistant Pseudomonas aeruginosa infections
- (2014) G. Samonis et al. INFECTION
- Pseudomonas aeruginosa bacteraemia: independent risk factors for mortality and impact of resistance on outcome
- (2014) Raquel Cavalcanti Dantas et al. JOURNAL OF MEDICAL MICROBIOLOGY
- Antibiotic Resistance inPseudomonas Aeruginosais Associated with Decreased Fitness
- (2013) Zhenzhen Sun et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Enhanced in vivo fitness of carbapenem-resistant oprD mutants of Pseudomonas aeruginosa revealed through high-throughput sequencing
- (2013) D. Skurnik et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Genetic Markers of Widespread Extensively Drug-Resistant Pseudomonas aeruginosa High-Risk Clones
- (2012) Gabriel Cabot et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Combination Therapy for Treatment of Infections with Gram-Negative Bacteria
- (2012) P. D. Tamma et al. CLINICAL MICROBIOLOGY REVIEWS
- Carbapenem-resistant Pseudomonas aeruginosa pneumonia with intermediate minimum inhibitory concentrations to doripenem: combination therapy with high-dose, 4-h infusion of doripenem plus fosfomycin versus intravenous colistin plus fosfomycin
- (2012) Anucha Apisarnthanarak et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Prospective Multicenter Study of the Impact of Carbapenem Resistance on Mortality in Pseudomonas aeruginosa Bloodstream Infections
- (2011) Carmen Peña et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance
- (2011) A.-P. Magiorakos et al. CLINICAL MICROBIOLOGY AND INFECTION
- Risk Factors for Mortality in Patients with Pseudomonas aeruginosa Bacteremia: Clinical Impact of Antimicrobial Resistance on Outcome
- (2011) Eun-Jeong Joo et al. Microbial Drug Resistance
- Impact of Multidrug-Resistant Pseudomonas aeruginosa Bacteremia on Patient Outcomes
- (2010) V. H. Tam et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Influence of carbapenem resistance on mortality and the dynamics of mortality in Pseudomonas aeruginosa bloodstream infection
- (2010) Cristina Suárez et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Antibiotic resistance and its cost: is it possible to reverse resistance?
- (2010) Dan I. Andersson et al. NATURE REVIEWS MICROBIOLOGY
- SCORING SYSTEMS FOR PREDICTION OF MORTALITY IN PATIENTS WITH INTENSIVE CARE UNIT-ACQUIRED SEPSIS
- (2009) Ji-Young Rhee et al. SHOCK
- Broad‐Spectrum Antimicrobials and the Treatment of Serious Bacterial Infections: Getting It Right Up Front
- (2008) Marin H. Kollef CLINICAL INFECTIOUS DISEASES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now